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ABSTRACT: Huperzine A (1, Hup A), a lycodine-type Lycopodium alkaloid isolated from Thai clubmosses Huperzia squarrosa (G.
Forst.) Trevis., H. carinata (Desv. ex. Poir.) Trevis., H. phlegmaria (L.), and Phlegmariurus nummulariifolius (Blume) Chambers
(Lycopodiaceae), exerts inhibitory activity on acetylcholinesterase, a known target for Alzheimer’s disease therapy. This study
investigated the structure−activity relationship of C(2)-functionalized and O- or N-methyl-substituted huperzine A derivatives. In
silico-guided screening was performed to search for potential active compounds. Molecular docking analysis suggested that
substitution at the C(2) position of Hup A with small functional groups could enhance binding affinity with AChE. Consequently,
12 C(2)-functionalized and four O- or N-methyl-substituted compounds were semi-synthesized and evaluated for their eeAChE and
eqBChE inhibitory activities. The result showed that 2-methoxyhuperzine A (10) displayed moderate to high eeAChE inhibitory
potency (IC50 = 0.16 μM) with the best selectivity over eqBChE (selectivity index = 3633). Notably, this work showed a case of
which computational analysis could be utilized as a tool to rationally screen and design promising drug molecules, getting rid of
impotent molecules before going more deeply on labor-intensive and time-consuming drug discovery and development processes.
■ INTRODUCTION
Alzheimer’s disease (AD), a dementia-related neurodegener-
ative brain disorder, is characterized by progressive cognitive
impairment according to increments in atrophy or loss of
neurons and synapse interneurons.1 AD ranks in the top-five
leading causes of global disability-adjusted life-years in patients
aged 75 years and older.2 Alzheimer’s Disease International
estimates that there are over 50 million people globally
suffering from dementia and the number tends to increase to
152 million by 2050.3 The characteristic pathologic hallmark of
AD relates to cholinergic neuronal death in basal forebrain,
neocortex, and hippocampus regions caused by deposition of
amyloid-beta (Aβ) plaque and neurofibrillary tangle (NFT) in
the brain.4
Acetylcholinesterase (AChE) is an essential enzyme that
plays a key role in controlling the acetylcholine (ACh)
neurotransmitter level, affecting cholinergic neurotransmis-
sion.5 Boosting the level of ACh by AChE inhibitors is an
effective symptomatic treatment of mild to moderate AD,
approved by USFDA.6 However, in advanced stages of AD, the
use of AChE inhibitors is limited due to peripheral cholinergic
side effects caused by nonselective inhibition of butyrylcholi-
nesterase (BChE).7,8 Thus to improve the efficacy and safety of
symptomatic AD treatment, the development of central
nervous system-selective AChE inhibitors without peripheral
side effects is crucial.
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(−)-Huperzine A (HupA (1), Figure 1) is a lycodine-type
Lycopodium alkaloid that was first isolated from Chinese
clubmoss Huperzia serrata (family Lycopodiaceae). HupA is a
potent inhibitor of AChE (IC50 = 0.02 μM toward hAChE)
9
and has been used (as a dietary supplement) to treat mild
AD.10 Although clinical studies still showed ambiguous results
on the improvement of cognitive function in AD patients,11,12
the core structure of HupA is a promising lead moiety, which
can be derivatized for the development of AChE inhibitors
with improved selectivity and efficacy. In our recent studies,
(−)-HupA (1) was isolated from alkaloid-rich fractions
clubmosses Huperzia squarrosa (G. Forst.) Trevis., H. carinata
(Desv. ex. Poir.) Trevis., H. phlegmaria (L.), and Phlegmariurus
nummulariifolius (Blume) Chambers (Lycopodiaceae) in large
quantities.13−15 With HupA in hand, chemical modifications
were performed on the pyridone ring moiety by in silico-guided
screening for potential active compounds as AChE inhibitors.
Our preliminary docking was carried out to visualize the key
interactions between HupA and human AChE by using Bristol
University Docking Engine (BUDE) and Sire Waterswap
molecular simulation. Using the BUDE, HupA was docked into
the crystal structures of recombinant human AChE (hAChE)
in all three forms: hAChE in the apo state (PDB ID: 4EY4),
hAChE complexing with HupA (PDB ID: 4EY5), and hAChE
complexing with donepezil (PDB ID: 4EY7). BUDE managed
to dock HupA into only the two forms of hAChE, 4EY4 and
4EY7, but it cannot re-dock HupA into the original hAChE in
complex with HupA form (4EY5) (see Table S1, Supporting
Information), which indicated that force field parameters and
the binding free energy equation of BUDE were limited to
analyze molecular docking accurately.16 This led us to use the
Figure 1. Structure of (−)-huperzine A (1) and club mosses (a) H. squarrosa, (b) H. carinata, (c) H. phlegmaria, and (d) P. nummulariifolius.
Figure 2. Molecular docking of HupA with AChE (4EY5) from BUDE and Sire Waterswap.
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AutoDock software for docking instead of BUDE, which is
capable to re-dock HupA into original hAChE of 4EY5. This
showed that the pyridone ring of HupA was positioned in the
space between Ser125, Gln71, and Trp86 of the catalytic
anionic site (CAS) of the crystallized structure of hAChE
(4EY5) with distances of 4.141, 5.870, and 4.019 Å,
respectively (Figure 2).17 These results suggested that the
substitution at C(2) of HupA could enhance binding affinity
with AChE. Though there are previous reports on derivatiza-
tion of HupA for AChE inhibition, including modifications at
the exocyclic ethylidene group,18 the pyridone ring,19 the
primary amine,9,20 and the C(6) methylene position,21−24 to
the best of our knowledge, C(2) modification has not been
investigated. Here, we report (i) the rational design of C(2)-
functionalized HupA analogs guided by in silico studies
(molecular docking and pharmacokinetic properties predic-
tion); (ii) the semi-synthesis of the selected C(2)-function-
alized HupA analogs; (iii) in vitro inhibitory activity of these
novel analogs on electric eel AChE (eeAChE) and equine
serum BChE (eqBChE); and (iv) structure−activity relation-
ship (SAR) analysis of the C(2) HupA analogs described in
this paper.
■ RESULTS AND DISCUSSION
In Silico-Guided Rational Drug Design. The C(2)
functionalization of HupA was designed to enhance molecular
interactions of the HupA derivatives with AChE. Twenty-eight
molecules, including C(2)-functionalized and O- or N-methyl-
substituted HupA analogs, were subjected to SwissADME
database (http://www.swissadme.ch/) to screen for drug-like
characteristics and associated pharmacokinetic properties.
Among this group, 12 C(2)-functionalized and four O- or N-
methyl-substituted HupA analogs met the criteria of Lipinski’s
rules and blood−brain barrier (BBB) permeability (Figure 3).
Molecular docking studies of these selected HupA derivatives
(with C(2) substituents including halogens, small alkyl groups,
hydroxyl, amino, nitrile, and small alkoxy groups) were then
performed using Autodock software.25,26 As shown in Table 1,
C(2) analogs 5, 6, 8, 9, and 10 yielded lower binding free
energies with AChE than that determined for the parent
compound 1.
Physicochemical Properties. The calculated physio-
chemical properties of the preselected HupA derivatives,
such as the number of H-bond acceptors (HBA), number of
H-bond donors (HBD), number of rotatable bonds (RB),
topological polar surface area (tPSA), and calculated n-
octanol/water partition coefficient (cLogP) were predicted,
as shown in Table 2. The results demonstrated that most
derivatives fell within the scope of Lipinski’s rule of five except
parent compound 1 and HupA analogs 7−10 where cLogP
values were not within the orally available drug range.27 For
blood−brain barrier permeability, the logarithm of the brain to
blood concentration ratio (log BB) was calculated by using
Clark’s model to determine the characteristic of the passages of
the HupA derivatives through the BBB.28 The predicted log
BB values of all derivatives were greater than −1, which
affirmed the possibility that these derivatives could be
developed into CNS drugs.28
Synthesis of HupA Derivatives. We focused on the use
of a range of metal-catalyzed transformations based on a C(2)-
halogenated variant of HupA as a synthetic entry to the C(2)
analogs that had been identified by in silico assessment. To
avoid interference by the existing (albeit very hindered)
primary amine of HupA, the amino group needed to be
protected.31 Three common protecting groups including tert-
butyloxycarbonyl (Boc), acetyl (Ac), and triflate (Tf) were
chosen as our first trials to search for the suitable protecting
groups (see the Supporting Information, Scheme S1).32 When
Figure 3. Design strategy for novel C(2) HupA derivatives targeting AChE.
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HupA was treated with acetyl chloride in the presence of
pyridine, the isomerized product 19 was observed based on
NMR, possibly due to in situ generation of HCl or acetic
acid.33 Isomerization was avoided when HupA was treated
with acetic anhydride,34 and the desired acetyl-protected
HupA 18 was isolated in 64% yield. The N-Tf- and N-Boc-
protected variants 20 and 21 were prepared35,36 and isolated in
38 and 29% yields, respectively, reflecting the hindered nature
of this amine moiety. The acetyl-protected variant 18 was the
most suitable since the protected HupA could be prepared in
moderate yield and the acetyl group is removable under basic
conditions, thus mitigating any risk of acid-promoted alkene
isomerization.37 Halogenation of N-Ac HupA 18 was carried
out under standard conditions38,39 to give the corresponding 2-
bromo and 2-iodo derivatives 22 and 23 in good yields;
however, we were then unable to remove the N-acetamide
residue (see the Supporting Information, Scheme S1).
Given the reactivity associated with pyridone toward
electrophilic substitution (which would favor reaction at
C(2))40 coupled with the hindered nature of the primary
amino moiety, we explored an alternative approach, avoiding
N-protection, as shown in Scheme 1. Unprotected HupA 1
underwent smooth and efficient electrophilic halogenation to
give 2-bromohuperzine A (2) and 2-iodohuperzine A (3),38,39
which then became attractive building blocks for further
functionalization via various types of cross-coupling reactions.
2-Fluorohuperzine A (4) was then prepared from iodide 3
r e a c t i n g w i t h 1 - c h l o r om e t h y l - 4 - fl u o r o - 1 , 4 -
diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) using Pd-
(dppf)Cl2 as a catalyst in THF under reflux for 96 h.
41 2-Alkyl
HupA derivatives were prepared using Kumada or Negishi
cross-coupling reactions.42,43 The reaction of iodide 3 using
Negishi’s method was found to be more effective, affording the
methylated and ethylated analogs 5 and 6 in 69 and 86%
yields, respectively. The bromo analog 2 was, however, inert
under these conditions. 2-Cyanohuperzine A (7) was prepared
in 53% yield from 3 by the L-proline-promoted Rosenmund−
von Braun reaction at 120 °C.44 The copper-catalyzed
heteroarene amination of 3 gave 2-aminohuperzine A (8)44
in 90% yield. Since the corresponding 2-hydroxy was observed
as a byproduct,45 these conditions were adapted to provide 2-
hydroxyhuperzine A (9) in 64% yield using water as a
hydroxide source, instead of aqueous ammonia solution. With
the successful and simple synthetic methods for 8 and 9, the 2-
alkoxy-HupA derivatives (10−13) were prepared by using an
alcohol as the nucleophilic component to provide 10−13 in
fair to good yields.
In addition to the C(2) functionalization of HupA, the
modification of the pyridone ring of HupA into O-alkyl
pyridine derivatives was performed to extend the structure−
activity relationship (SAR) to O- or N-methyl-substituted
HupA and O- or N-unsubstituted HupA, as shown in Scheme
Table 1. Molecular Docking Analysis of Compounds 1−17 against hAChE (4EY5) and hBChE (4XII) Using Autodock
Software


















HupA 1 −12.17 1.20 Tyr337 (2.90), Tyr133
(2.75, 3.15)
−8.08 1.20 μM Glu197 (2.50)
2 −12.10 1.34 Tyr133 (2.92) −9.21 177.89
3 −10.63 16.24 Tyr133 (2.51), Gly120
(3.15)
−8.87 313.41 Asp70 (2.48), Thr120
(2.36), Tyr332 (2.99)
4 −12.00 1.62 Tyr133 (2.87) −8.65 453.73 Glu197 (2.77)
5 −12.20 1.13 Tyr133 (2.90, 3.15) 8.33 780.19 Asp70 (2.38), Tyr332
(2.69)
6 −12.31 0.95 Tyr133 (2.78) −8.92 290.98
7 −10.25 30.64 Tyr133 (2.92), Tyr337
(2.84)
−8.91 296.05
8 −12.19 1.17 Trp86 (2.98), Tyr133
(2.87)
−8.65 458.89 Tyr128 (2.43), Glu197
(2.74)
9 −12.47 0.73 Trp86 (2.91), Tyr133
(2.89)
−8.86 321.81 Tyr128 (2.43), Glu197
(2.78)
10 −12.75 0.45 Tyr133 (2.84), Glu202
(2.70)
−9.40 129.68 Glu197 (2.51)
11 −11.30 5.23 Gly120 (2.75), Tyr133
(2.64)
−8.64 468.08 Asp70 (2.36), Tyr
(2.68)
12 −11.04 8.13 −8.89 302.29 Asp70 (2.49), Tyr332
(2.67)
13 −8.45 643.06 −8.77 370.76 Glu197 (2.97), His438
(2.77)
14 −12.21 1.11 Glu202 (2.53) −8.99 258.05 Glu197 (2.65)
15 −8.39 713.34 Ser203 (2.61), His447
(3.22)
−7.29 4.50 μM Ser198 (3.29), His438
(2.68)
16 −9.11 211.03 Gly120 (2.99) −7.38 3.88 μM
17 −7.63 2.56 μM −7.55 2.91 μM Ser79 (3.09)
donepezilc −12.42 0.78 Phe295 (2.99) −9.99 47.44
aBinding free energy and inhibitory constant results obtained from AutoDock 4.2.6 software.25 bMolecular docking visualization and H-bonding
measurement of each compound were obtained from UCSF Chimera Molecular graphics, and analyses were performed with UCSF Chimera.26
cDonepezil, a known selective AChE inhibitor.29
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2. By following a protocol reported by White and co-workers,46
O-methyl-substituted HupA (14) was obtained in 46% yield by
treatment of 1 with an excess of iodomethane and Ag2CO3 for
45 h at room temperature. When the reaction time was
increased to 72 h, a mixture of O- or N-methyl-substituted
HupA including N,N,O-trimethyl huperzine A (15, 19%),
Table 2. Physiochemical Properties of Compounds 1−17
compound MWa HBAb HBDb RBb tPSAb cLogPb log BBc
1 242.32 2 2 0 58.88 1.88 −0.45
2 321.22 2 2 0 58.88 2.53 −0.35
3 368.22 2 2 0 58.88 2.56 −0.34
4 260.31 3 2 0 58.88 2.26 −0.39
5 256.35 2 2 0 58.88 2.22 −0.39
6 270.38 2 2 1 58.88 2.55 −0.34
7 267.33 3 2 0 82.67 1.71 −0.82
8 257.34 2 3 0 84.90 1.40 −0.90
9 258.32 3 3 0 79.11 1.58 −0.79
10 272.35 3 2 1 68.11 1.88 −0.58
11 286.38 3 2 2 68.11 2.21 −0.53
12 300.40 3 2 3 68.11 2.57 −0.48
13 314.43 3 2 4 68.11 2.91 −0.43
14 256.35 3 1 1 48.14 2.50 −0.19
15 284.40 3 0 2 25.36 3.09 0.23
16 284.40 2 0 1 25.36 3.09 0.23
17 270.37 2 1 1 36.10 2.92 0.05
donepezild 381.51 4 0 6 38.77 3.85 0.15
required parameterse <500 <10 <5 <10 <90 2−5 >−1.00
aCalculated using ChemBioDraw Ultra16.0. MW: molecular weight. bCalculated using SwissADME (http://www.swissadme.ch/).30 HBA: number
of hydrogen acceptors; HBD: number of hydrogen donors; RB: number of rotatable bonds; tPSA: total polar surface area; cLog P: log octanol/
water partition coefficient. clog BB = −0.0148 × tPSA + 0.152 × cLogP + 0.139.28 dDonepezil, a known selective AChE inhibitor.29 eRequired
parameters necessary to fulfill appropriate physiochemical properties as judged appropriately according to Lipinski’s rules and those important for
BBB permeation.27
Scheme 1. Synthesis of C(2)-Functionalized HupA Derivatives 2−13a
aReaction conditions: (a) NBS, DCM, RT, 24 h; (b) NIS, DCM, RT, 48 h; (c) 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane
bis(tetrafluoroborate), Pd(dppf)Cl2, THF, reflux, 96 h; (d) CH3MgBr, Pd(dppf)Cl2, THF, reflux, 72 h; (e) Zn(CH3)2, Pd(dppf)Cl2, THF, reflux,
72 h; (f) Zn(CH2CH3)2, Pd(dppf)Cl2, THF, reflux, 72 h; (g) CuCN, K2CO3, DMF, 120 °C, 72 h; (h) NH3 (aq.), CuI, K2CO3, 140 °C, 72 h; (i)
H2O, CuI, K2CO3, 130 °C, 72 h; (j) MeOH, CuI, K2CO3, 140 °C, 72 h; (k) EtOH, CuI, K2CO3, 140 °C, 72 h; (l) n-PrOH, CuI, K2CO3, 140 °C,
72 h; (m) n-BuOH, CuI, K2CO3, 140 °C, 72 h.
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N,N,N-trimethyl huperzine A (16, 26%), and N,N-dimethyl
huperzine A (17, 10%) was isolated.
In Vitro eeAChE and eqBChE Inhibition Assays. AChE
is the esterase responsible for the regulation of cholinergic
transmission via hydrolysis of Ach, which is a primary
neurotransmitter of sympathetic and parasympathetic gan-
glionic neurons.8 Inhibitors of AChE can alleviate the
symptoms of ACh decline by increasing cerebral cholinergic
transmission at the synaptic cleft4 and three AChE inhibitors,
donepezil, rivastigmine, and galantamine, are currently
approved for the treatment of AD.47 While rivastigmine is a
reversible cholinesterase inhibitor that targets both AChE and
BChE,29,48 donepezil and galantamine display better selectivity
for AChE.
The in vitro activities of the HupA analogs 2−17 prepared to
inhibit eeAChE and eqBChE were assessed using Ellman’s
method,49 using donepezil as the reference compound. All
compounds were screened at a concentration of 10 μM, and
IC50 values were determined where inhibition was observed.
The results for screening against AChE and BChE are shown
in Table 3. Among C(2)-functionalized HupA derivatives,
compounds 10 and 11 displayed the best eeAChE inhibitory
activity with IC50 values of 0.16 and 0.22 μM, respectively,
comparable to that of donepezil (IC50 = 0.23 μM). Although
the enzyme inhibitory results did not track exactly the
calculated inhibition constants reported in Table 1, all
derivatives tested were less potent than the parent compound
HupA 1 (IC50 = 0.03 μM). This observation is in accordance
with many related studies of the AChE and/or BChE
inhibitory activity of HupA derivatives.50 Most of HupA
analogs with substitutions at different positions on the skeleton
were inactive or less active as an AChE inhibitor than HupA
itself.50 Moreover, while some analogs did show improved
activities, this was also linked to a decrease in selectivity. For
example, Kozikowski and co-workers22 reported that intro-
duction of small substituents, such as methyl or ethyl groups, at
C(6) of HupA increased the inhibitory potency for AChE
(IC50 ranging from 0.003−2.04 μM toward FBS AChE),
compared to the parent compound (IC50 = 0.024 μM), but
they also saw a reduction in selectivity in terms of the BChE/
AChE inhibitory activity ratio.22 Since 2-methoxy-HupA 10
displayed both a comparable level of activity to that of
donepezil and better selectivity (selectivity index = 3633) to
inhibit eeAChE over eqBChE than the HupA 1 and donepezil,
Scheme 2. Synthesis of HupA Derivatives 14−17a
aReaction conditions: (a) CH3I, Ag2CO3, DCM, RT, 45 h; (b) CH3I, Ag2CO3, DCM, RT, 72 h.
Table 3. In Vitro Inhibitory Activity of Compounds 1−17 toward Cholinesterases
cholinesterase IC50 (μM)
a
compound R1 R2 R3 R4 eeAChEb eqBChEc SId
1 H H H H 0.03 ± 0.00 68.78 ± 03.15 2,273
2 Br H H H 2.56 ± 0.17 72.29 ± 04.57 28
3 I H H H 14.12 ± 0.84 325.22 ± 38.63 23
4 F H H H 1.23 ± 0.01 63.998 ± 03.63 52
5 Me H H H 0.35 ± 0.02 486.03 ± 29.71 1,388
6 Et H H H 0.57 ± 0.09 60.39 ± 02.54 105
7 CN H H H 33.88 ± 1.95 1,050.88 ± 498.89 31
8 NH2 H H H 0.32 ± 0.01 524.64 ± 41.56 1,634
9 OH H H H 0.53 ± 0.09 154.76 ± 04.14 293
10 OMe H H H 0.16 ± 0.02 599.15 ± 49.76 3,633
11 OEt H H H 0.22 ± 0.04 253.02 ± 12.24 1,154
12 OnPr H H H 10.19 ± 0.50 87.27 ± 01.37 9
13 OnBu H H H 109.65 ± 9.59 16.91 ± 01.23 0.2
14 H H 3.67 ± 0.28 903.66 ± 88.20 246
15 Me Me n.i. 1,348.75 ± 62.31
16 Me Me Me n.i. 258.70 ± 10.81
17 Me Me 0.61 ± 0.02 223.57 ± 47.78 366
donepezile 0.23 ± 0.05 18.00 ± 00.79 79
aMean IC50 (μM) ± SEM, n = 3; n.i. = no inhibition.
bAChE (EC 3.1.1.7) from electric eel. cBChE (EC 3.1.1.8) from horse serum. dSelectivity
index for AChE is defined as IC50 (BChE)/IC50 (AChE).
eDonepezil, a known selective AChE inhibitor used as a positive control.29
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this is a variant that could be assessed more fully for its
potential for AD treatment.
Regarding the predicted physiochemical properties of HupA
derivatives, as shown in Table 2, compound 10 has properties
that fall within the range of the “CNS drug” compound. We
observed the high log BB (>−1.0) of compound 10 that has
small size and is less polar (lower number of hydrogen
acceptors, lower number of hydrogen donors, and lower tPSA
value) as parent compound 1, suggesting that this compound
could pass the BBB to alleviate the ACh level at CNS.
Structure−Activity Relationship Analysis. The relation-
ship between the structures of C(2)-functionalized HupA
derivatives and cholinesterase IC50 values were evaluated.
Introduction of halogen substituents (compounds 2−4)
showed a decrease in eeAChE inhibitory activity. Increasing
atomic radius sizes of halogen atoms also resulted in decreasing
eeAChE inhibitory activity. For the linear alkyl side chains, IC50
values against eeAChE were elevated corresponding to the
carbon numbers; from HupA 1 (0.03 ± 0.00 μM) to methy
HupA 5 (0.35 ± 0.02 μM) and ethyl HupA 6 (0.57 ± 0.09
μM). Likewise, 2-methoxy-Hup A (10) was the most potent
eeAChE inhibitor, compared to the other alkoxy derivatives
11−13 assessed, while conversely, the n-butoxy variant 13
preferably inhibited eqBChE. These observations can be
explained by the bulk of the substituent at the C(2) position,
preventing entry of the molecules into the AChE active site.
The molecular docking and binding mode analysis of 10 and
13 confirmed the steric influence of alkoxy side chains at the
C(2) position (Figure 4). The methoxy group of 10 positioned
in the space between Gln69, Trp84, and Ser122 of AChE by
the formation of hydrogen bonding between the 2-methoxy
and hydroxyl oxygen of Tyr133 of AChE. This alignment fitted
the hydrophobic region in CAS of AChE, resulting in the
stronger binding to the enzymatic active site. The steric
hindrance associated with the large alkyl side chain in
compound 13 disrupted the binding affinity to the active site
of AChE, giving the least favorable binding free energy
(estimated binding free energy, −8.45 kcal/mol). Similarly, the
binding mode analysis of compounds 10 and 13 within the
BChE active site was also conducted, as shown in Figure 5.
Both compounds occupy the space between Trp82, Tyr128,
Glu167, and His438 of BChE with the same alignment as the
parent compound 1. The primary amine in compounds 10 and
13 interacted directly with carboxylate oxygen of Glu197 by H-
bonding, while hydrophobic interactions were formed between
the bicyclic moiety of the ligand and the indole ring of Trp82
in the same manner. On the other hand, the butoxy derivative
13 situated in the space between Trp231, Leu286, Val288, and
Phe329 of BChE. The primary amine of 13 consequently
interacted with the imidazole ring of His438 of BChE by H-
bonding, corresponding to the lowest in vitro IC50 value for
eqBChE activity inhibition.
The reliability of in silico-guided analysis was determined by
correlation of estimated Ki (from docking analysis) and
experimentally determined Ki (from the in vitro AChE
inhibitory assay) values. According to the known inhibition
mode of HupA, we deduce that C(2)-functionalized HupA
derivatives 2−13 are competitive inhibitors. The experimental
Figure 4. (a, b) Molecular docking and (c, d) binding mode analysis of compounds 10 and 13 toward AChE (4EY5).
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Ki values of all derivatives were calculated from in vitro IC50
values using the equations proposed by Cer and co-workers (Ki
= IC50/2).
51 Pearson’s and Spearman’s correlation coefficients
for regression between the Ki values were also analyzed (Figure
6). The results demonstrated that the relationship between
estimated Ki and experimentally determined Ki has a significant
positive trend where both correlation coefficients are greater
than zero (Pearson’s and Spearman’s coefficients of 0.96 and
0.78, respectively). The result suggested that in silico-guided
analysis could be utilized as a reliable tool for rational drug
design.
In addition to C(2)-functionalized derivatives, the struc-
ture−activity relationship of the O- or N-methyl-substituted
HupA analogs was also analyzed. All O- or N-methyl-
substituted HupA derivatives 14−17 exhibited less potent
inhibitory activity on eeAChE than HupA 1. The N- or O-
methylated HupA derivatives, such as N,N,O-trimethyl HupA
(15) and N,N,N-trimethyl HupA (16), showed no inhibition
of eeAChE, corresponding to the in silico analysis that had
indicated that the heteroatoms of both the pyridone ring and
primary amine of HupA were necessary for binding to the
active site of AChE. N,N-Dimethyl HupA (17) showed greater
eeAChE inhibitory activity than the O-methyl HupA (14),
suggesting that interactions involving the pyridone ring of
HupA were more crucial than the amino group for AChE
inhibition. Methyl substitution at the nitrogen pyridone ring of
HupA has been evaluated for the AChE inhibitory activity.18
This compound showed low potency for brain AChE
inhibitory activity, similar to the activity that we observed for
compound 16. Moreover, the transformation of the pyridine
ring from the pyridone ring of HupA as catechol analogs was
also reported with inactivity or less activity than HupA in
AChE.24
To evaluate the cytotoxicity of the HupA derivatives
reported here and donepezil, an MTT (3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was per-
formed. Each compound was tested at two concentrations, 10
and 100 μM, against human lung fibroblast cells (IMR90). As
demonstrated in Table 4, at 10 μM concentration, all
compounds failed to affect the cell proliferation. Among
them (and at 100 μM), only 6, 15, and donepezil showed some
cytotoxicity while compound 6 was still significantly less toxic
than donepezil. Interestingly, we did not observe any cell
toxicity for ligand 10, which is the most promising selective
inhibitor that we have identified.
Figure 5. (a, b) Molecular docking and (c, d) binding mode analysis of compounds 10 and 13 toward BChE (4XII).
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■ CONCLUSIONS
In this paper, we report the semi-synthesis of a set of novel
C(2)-functionalized HupA derivatives that were designed
using in silico binding affinity to AChE and predicted the
pharmacokinetic properties. Among the variants synthesized,
2-methoxy-HupA 10 was found to be the most potent eeAChE
inhibitor with improved selectivity over eqBChE, compared to
HupA (∼2 times) and donepezil (∼46 times). In addition,
using an MTT assay, ligand 10 was significantly less cytotoxic
than donepezil. These results suggested the potential of ligand
10 to be further developed as an AD treatment with less
peripheral side effects. The structure−activity relationship of
the O- or N-methyl-substituted HupA compounds 14−17 was
also studied. The results revealed that the nitrogen atom of the
pyridone ring, rather than the primary amine of HupA, was
crucial for AChE binding. The detailed structure−activity
relationship analysis of HupA derivatives reported here should
be useful for the future development of anti-AD drugs.
■ EXPERIMENTAL SECTION
Computational Analysis. Preparation of the Structures
of HupA Derivatives. Structures of HupA and its analogs were
constructed in ChemDraw Professional 16.0 followed by three-
dimensional (3D) structure transformation using Chem3D
Professional 10.0. All analogs were then energetically
minimized by Chem3D Professional 10.0 by using the MM2
force field to avoid any steric clashes of the freely rotatable
bond.
Molecular Docking of HupA Analogs into AChE. The
binding free energy and inhibitory constant Ki of HupA, HupA
analogs, and donepezil (as a reference compound with AChE
inhibition) were docked and analyzed by using AutoDock 4.2.6
software. The crystal structures of human AChE (PDB entry:
4EY5) and BChE (PDB entry: 4XII) were prepared by
removing all water molecules, any solvent, and the ligand. Each
energy-minimized HupA analogs were submitted with default
parameters of docking procedures. The binding site sphere for
HupA derivatives interaction was defined around the catalytic
site according to previous studies (Tyr72, Asp74, Trp86,
Gly121, Gly122, Glu202, Ser203, Ala204, Trp236, Trp286,
Phe295, Phe297, Glu334, Tyr337, Phe338, and His447 for the
AChE active site and Trp82, Trp231, Phe329, and Tyr332 for
the BChE active site). The Ser124 and Gln71 residues were
also included to determine the free pocket space of AChE for
the C(2) functional group of HupA derivatives. The molecular
docking protocol was obtained from the active site of the
Figure 6. Correlation of the estimated Ki value according to the docking program and calculated Ki according to in vitro results. Correlation is
significant at the p < 0.001 level (two-tailed).
Table 4. In Vitro Cytotoxicity of HupA Derivatives and
Donepezil against IMR90 Cellsa
%cytotoxicityb %cytotoxicityb
compound 10 μM 100 μM compound 10 μM 100 μM
1 n.i. n.i. 10 n.i. n.i.
2 n.i. n.i. 11 n.i. n.i.
3 n.i. n.i. 12 n.i. n.i.
4 n.i. n.i. 13 n.i. n.i.
5 n.i. n.i. 14 n.i. n.i.
6 n.i. 2.2 ± 2.4c 15 n.i. 5.5 ± 9.7
7 n.i. n.i. 16 n.i. n.i.
8 n.i. n.i. 17 n.i. n.i.
9 n.i. n.i. donepezil n.i. 29.0 ± 12.5
aIMR90 cells were treated with each compound at the indicated
concentrations for 24 h. Cell viability was determined by the MTT
assay. bThe values are shown as mean ± SEM, n = 3. n.i. = no
inhibition. cSignificantly different from donepezil (100 μM) with p <
0.05.
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AChE and BChE with a molecular grid at 0.375 Å grid spacing.
The grids were located at x = −6.750, y = −6.250, and z =
3.389 Å for AChE and x = 4.302, y = −7.649, and z = −14.515
Å for BChE. Docking results of all HupA analogs with AChE
and BChE were evaluated as the best binding free energy (BE,
kcal/mol) and inhibitory constant Ki from all clusters of each
conformational structure. Virtual analysis of the best result of
each analog was viewed and analyzed by using UCSF
Chimera.26
Computational Pharmacokinetic Analysis. The Swis-
sADME is a free web tool to compute the physicochemical
properties of a small molecule to evaluate lead candidates of
HupA analogs (http://www.swissadme.ch/index.php).30 All
analogs were submitted in the SMILES format to calculate the
pharmacokinetic properties of HupA analog candidates. The
physicochemical properties of SwissADME results include
molecular weight (MW), number of heavy atoms, number of
the rotatable bonds, number of H-bond acceptors (HA),
number of H-bond donors, polar surface area (PSA), and
lipophilicity were obtained.
Semi-synthesis of HupA Analogs. General Chemistry.
The HupA (1) starting material was isolated from clubmosses
H. squarrosa (G. Forst.) Trevis., H. carinata (Desv. ex. Poir.)
Trevis., H. phlegmaria (L.), and P. nummulariifolius (Blume)
Chambers (Lycopodiaceae),13−15 and used in the semi-
synthesis of N-protection of HupA derivatives (Scheme 2
and Scheme S1). Commercial HupA (99% purity) was
purchased from Changsha Zhongren Biotechnology (Chang-
sha City, Hunan, China) and used in the semi-synthesis of
C(2)-functionalized HupA derivatives, as shown in Scheme 1.
All reagents and solvents were obtained from commercial
suppliers and used without further purification. The reactions
were performed based on previously published procedures and
monitored by thin-layer chromatography (TLC) on silica gel
pre-coated aluminum plates (70−230 mesh). The TLC spots
were visualized by UV light at 254 and 365 nm. The
purification of all desired products was carried out by using
silica gel column chromatography (70−230 mesh of SiliCycle
silica gel), which provided isolated yield. 1H and 13C NMR
spectra were collected on a Bruker AVANCE at 300 and 75
MHz, respectively. Chemical shifts (δ) were reported in parts-
per-million (ppm) relative to residual solvent signals. The 1D
spectra was measured in CDCl3, which were referenced to 7.26
ppm for 1H NMR and 77 ppm for 13C NMR. High-resolution
mass spectra were obtained using electron spray ionization
(ESI) on a Thermo Scientific QTOF instrument.
Formation of Compound 2 by Bromination of Huperzine
A (1)). HupA (1, 0.21 mmol, 50 mg) was treated with N-
bromosuccinimide (NBS, 0.62 mmol, 110 mg) in CH2Cl2 (1.0
mL) at room temperature for 24 h. The reaction mixture was
quenched with H2O (5 mL) and extracted three times with
CH2Cl2 (5 mL). The combined organic layers were washed
with sat. NaCl (5 mL), then dried over anhydrous Na2SO4,
and concentrated under reduced pressure. The crude product
was purified by flash column chromatography (4−7% v/v




one (2). Yellowish solid; m.p. 199−200 °C; [α]D26 −135.2° (c
2.5, CH3OH); Rf = 0.40 (7% v/v MeOH in CH2Cl2); IR
(neat) ν 2927, 1638, 1610, 1549, 1457, 600 cm−1; 1H NMR
(300 MHz, CDCl3) δH 8.30 (s, 1H), 5.49 (q, J = 6.6 Hz, 1H),
5.43 (d, J = 6.0 Hz, 1H), 3.60−3.66 (m, 1H), 2.88 (dd, J =
16.5, 6.0 Hz, 1H), 2.76 (dd, J = 16.5, 3.0 Hz, 1H), 2.13 (d, J =
6.0 Hz, 2H), 1.68 (d, J = 6.6 Hz, 3H), 1.56 (s, 3H); 13C NMR
(75 MHz, CDCl3) δC 161.4, 143.3, 142.3, 142.1, 134.1, 124.3,
124.0, 111.8, 111.74, 54.39, 49.24, 35.1, 32.8, 22.6, 12.4;
(+)-HRMS (ESI) m/z calcd for C15H18
79BrN2O [M + H]
+,
321.0597; found 321.0585.
Formation of Compound 3 by Iodination of Huperzine A
(1). HupA (1, 0.41 mmol, 100 mg) was treated with N-
iodosuccinimide (NIS, 0.62 mmol, 139 mg) in CH2Cl2 (2.5
mL) at room temperature for 72 h. The reaction mixture was
quenched with H2O (10 mL) and extracted three times with
CH2Cl2 (10 mL). The combined organic layers were washed
with sat. NaCl (10 mL), then dried over anhydrous Na2SO4,
and concentrated under reduced pressure. The crude product
was purified by flash column chromatography (7% v/v MeOH
in CH2Cl2) to afford 2-iodohuperzine A (3, 103 mg, 68%).
(5R,9R,E)-5-Amino-11-ethylidene-3-iodo-7-methyl-
5,6,9,10-tetrahydro-5,9-methanocycloocta[b]pyridin-2(1H)-
one (3). White-yellowish solid; m.p. 250−251 °C; [α]D26
−151.0° (c 4.0, CH3OH); Rf = 0.46 (7% v/v MeOH in
CH2Cl2); IR (neat) ν 2924, 1630, 1606, 1541, 1449, 589 cm
−1;
1H NMR (300 MHz, CDCl3) δH 8.49 (s, 1H), 5.46 (q, J = 6.6
Hz, 1H), 5.41 (d, J = 6.0 Hz, 1H), 3.59−3.63 (m, 1H), 2.85
(dd, J = 18.0, 6.0 Hz, 1H), 2.73 (dd, J = 18, 3.0 Hz, 1H), 2.11
(s, 2H), 1.65 (d, J = 6.6 Hz, 3H), 1.53 (s, 3H); 13C NMR (75
MHz, CDCl3) δC 162.4, 149.1, 144.5, 142.1, 134.1, 124.6,
124.4, 111.7, 87.3, 54.3, 49.3, 35.1, 32.8, 22.7, 12.5; (+)-HRMS
(ESI) m/z calcd for C15H18IN2O [M + H]
+, 369.0458; found
369.0451.
Formation of Compound 4 by Fluorination of 2-
Iodohuperzine A (3). To a solution of 2-iodohuperzine A (3,
0.14 mmol, 50 mg) in THF (1.0 mL) were added
bis(triphenylphosphine)palladium dichloride (20 mg, 4 mol
%) and 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]-
octane bis(tetrafluoroborate) (0.68 mmol, 241 mg). The
mixture was heated at reflux temperature for 96 h under an Ar
atmosphere. After cooling to room temperature, the reaction
mixture was quenched with H2O (10 mL) and extracted three
times with CH2Cl2 (10 mL). The combined organic layers
were washed with sat. NaCl (10 mL), then dried over
anhydrous Na2SO4, and concentrated under reduced pressure.
The crude product was purified by flash column chromatog-
raphy (5% v/v MeOH in ethyl acetate) to afford 2-
fluorohuperzine A (4, 6 mg, 16%).
(5R,9R,E)-5-Amino-11-ethylidene-3-fluoro-7-methyl-
5,6,9,10-tetrahydro-5,9-methanocycloocta[b]pyridin-2(1H)-
one (4). Yellowish semisolid; [α]D
26 −48.0° (c 1.0, CH3OH); Rf
= 0.2 (100% ethyl acetate); IR (neat) ν 2920, 1662, 1619,
1437, 1305 cm−1; 1H NMR (300 MHz, CDCl3) δH 7.74 (d, J =
6.0 Hz, 1H), 5.49 (q, J = 6.0 Hz, 1H), 5.41 (d, J = 3.0 Hz, 1H),
3.60−3.64 (m, 1H), 2.87 (d, J = 18.0 Hz, 1H), 2.70 (d, J =
18.0 Hz, 1H), 2.13 (s, 1H), 2.11 (s, 1H), 1.69 (d, J = 9.0 Hz,
3H), 1.56 (s, 3H); 13C NMR (75 MHz, CDCl3) δC 158.2,
138.1, 134.26, 124.3, 121.9, 121.7, 111.8, 77.4, 54.5, 49.1, 34.8,
33.0, 29.8, 22.7, 12.5; (+)-HRMS (ESI) m/z calcd for
C15H18FN2O [M + H]
+, 261.1398; found 261.1399.
Formation of Compound 5 by Methylation of 2-
Iodohuperzine A (3) Using the Negishi Cross-Coupling
Reaction. To a solution of 2-iodohuperzine A (3, 0.27 mmol,
100 mg) in THF (1 .0 mL) were added b i s -
(triphenylphosphine)palladium dichloride (22 mg, 10 mol
%) and dimethylzinc (0.81 mmol, 0.8 mL of 1 M dimethylzinc
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in toluene solution). The resulting yellow solution was heated
at reflux temperature for 72 h under an Ar atmosphere. After
cooling to room temperature, the reaction mixture was
quenched with methanol (1.0 mL) and tert-butyl methyl
ether (10 mL). The resulting mixture was washed three times
with water (10 mL) and sat. NaCl (10 mL), then dried over
anhydrous Na2SO4, and concentrated under reduced pressure.
The crude product was purified by flash column chromatog-
raphy (7% v/v MeOH in CH2Cl2) to afford 2-methylhuperzine
A (5, 46 mg, 67%).
(5R,9R,E)-5-Amino-11-ethylidene-3,7-dimethyl-5,6,9,10-
tetrahydro-5,9-methanocycloocta[b]pyridin-2(1H)-one (5).
Brownish solid; m.p. 83−85 °C; [α]D26 −150.0° (c 3.8,
CH3OH); Rf = 0.26 (7% v/v MeOH in CH2Cl2); IR (neat)
ν 2918, 1642, 1618, 1572, 1263 cm−1; 1H NMR (300 MHz,
CDCl3) δH 7.71 (s, 1H), 5.47 (q, J = 9.0 Hz, 1H), 5.41 (s, 1H),
3.55−3.65 (m, 1H), 2.87 (dd, J = 18.0, 3.0 Hz, 1H), 2.56 (d, J
= 15.0, 1H), 2.14 (s, 2H), 2.12 (s, 3H), 1.67 (d, J = 6.0 Hz,
3H), 1.54 (s, 3H); 13C NMR (75 MHz, CDCl3) δC 165.3,
142.9, 140.0, 137.4, 134.2, 125.8, 124.4, 122.1, 110.9, 54.4,
49.2, 35.0, 33.1, 22.7, 16.5, 12.4; (+)-HRMS (ESI) m/z calcd
for C16H21N2O [M + H]
+, 257.1648; found 257.1647.
Formation of Compound 6 by Ethylation of 2-
Iodohuperzine A (3) Using the Negishi Cross-Coupling
Reaction. To a solution of 2-iodohuperzine A (3, 0.27 mmol,
100 mg) in THF (1 .0 mL) were added b i s -
(triphenylphosphine)palladium dichloride (22 mg, 10 mol
%) and diethylzinc (0.81 mmol, 0.8 mL of 1 M diethylzinc in
toluene solution). The resulting yellow solution was heated at
reflux temperature for 72 h under an Ar atmosphere. After
cooling to room temperature, the reaction mixture was
quenched with methanol (1.0 mL) and tert-butyl methyl
ether (10 mL). The resulting mixture was washed three times
with water and sat. NaCl (10 mL), then dried over anhydrous
Na2SO4, and concentrated under reduced pressure. The crude
product was purified by flash column chromatography (7% v/v




one (6). Brownish solid; m.p. 243−244 °C; [α]D26 −173.0° (c
2.0, CH3OH); Rf = 0.31 (7% v/v MeOH in CH2Cl2); IR
(neat) ν 2972, 1643, 1620, 1568, 1264 cm−1; 1H NMR (300
MHz, CDCl3) δH 7.70 (s, 1H), 5.47 (q, J = 6.0 Hz, 1H), 5.39
(d, J = 3.0 Hz, 1H), 3.55−3.65 (m, 1H), 2.85 (dd, J = 18.0, 3.0
Hz, 1H), 2.66 (d, J = 18.0 Hz, 1H), 2.52 (q, J = 6.0 Hz, 2H),
2.19 (s, 1H), 2.10 (s, 1H), 1.67 (d, J = 6.0 Hz, 3H), 1.54 (s,
3H), 1.18 (t, J = 6.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δC
164.7, 142.6, 139.8, 135.6, 134.2, 131.7, 124.4, 122.1, 111.1,
54.5, 49.1, 35.0, 33.0, 23.4, 22.8, 13.1, 12.5; (+)-HRMS (ESI)
m/z for C17H23N2O [M + H]
+, 271.1805; found 271.1805.
Formation of Compound 7 by Cyanidation of 2-
Iodohuperzine A (3) Using the Rosenmund−von Braun
Reaction. To a solution of 2-iodohuperzine A (3, 0.14 mmol,
50 mg) in DMF (3.0 mL) were added CuCN (0.68 mmol, 61
mg) and K2CO3 (0.41 mmol, 56 mg). The mixture was heated
at 120 °C for 72 h under an Ar atmosphere. After cooling to
room temperature, the reaction mixture was quenched with
H2O (10 mL) and extracted three times with CH2Cl2 (10 mL).
The combined organic layers were washed with sat. NaCl (10
mL), then dried over anhydrous Na2SO4, and concentrated
under reduced pressure. The crude product was purified by
flash column chromatography (2−7% v/v MeOH in CH2Cl2)




Yellowish solid; m.p. 244−245 °C; [α]D26 −247.5° (c 1.6,
CH3OH); Rf = 0.46 (7% v/v MeOH in CH2Cl2); IR (neat) ν
2225, 1651, 1597, 1566, 1304 cm−1; 1H NMR (300 MHz,
CDCl3) δH 8.43 (s, 1H), 5.51 (q, J = 6.0 Hz, 1H), 5.54 (d, J =
6.0 Hz, 1H), 3.60−3.70 (m, 1H), 2.91 (dd, J = 18.0, 3.0 Hz,
1H), 2.84 (dd, J = 18.0, 1.5 Hz, 1H), 2.11 (s, 2H), 1.69 (d, J =
9.0 Hz, 3H), 1.54 (s, 3H); 13C NMR (75 MHz, CDCl3) δC
163.0, 150.9, 147.5, 141.5, 134.1, 124.5, 124.3, 116.2, 112.6,
101.3, 54.5, 49.6, 35.9, 32.6, 22.6, 12.5; (+)-HRMS (ESI) m/z
for C16H17N3O [M + H]
+, 268.1444; found 268.1447.
Formation of Compound 8 by Copper-Catalyzed
Heteroarene Amination of 2-Iodohuperzine A (3). 2-
Iodohuperzine A (3, 0.14 mmol, 50 mg), copper(I) iodide
(1 mg, 4 mol %), and K2CO3 (0.41 mmol, 56 mg) were
charged in a 15 mL sealed screw-capped tube under air, and
5.0 mL of aqueous ammonia solution (ca. 28%) was added via
a syringe. The sealed tube was closed tightly after purging with
argon gas flow. The reaction mixture was heated at 140 °C and
stirred for 72 h. After cooling to room temperature, the
reaction mixture was quenched with H2O (10 mL) and
extracted three times with CH2Cl2 (10 mL). The combined
organic layers were washed with sat. NaCl (10 mL), then dried
over anhydrous Na2SO4, and concentrated under reduced
pressure. The crude product was purified by flash column
chromatography (7−15% v/v MeOH in CH2Cl2) to afford 2-
aminohuperzine A (8, 32 mg, 90%).
(5R,9R,E)-3,5-Diamino-11-ethylidene-7-methyl-5,6,9,10-
tetrahydro-5,9-methanocycloocta[b]pyridin-2(1H)-one (8).
Yellowish solid; m.p. 82−84 °C; [α]D26 −145.3° (c 1.9,
CH3OH); Rf = 0.11 (10% v/v MeOH in CH2Cl2); IR
(neat) ν 3450, 3295, 1645, 1589, 1454 cm−1; 1H NMR (300
MHz, CD3OD) δH 7.06 (s, 1H), 5.50 (q, J = 6.0 Hz, 1H), 5.43
(d, J = 3.0 Hz, 1H), 3.60−3.70 (m, 1H), 2.75 (dd, J = 18.0, 6.0
Hz, 1H), 2.51 (dd, J = 18.0, 3.0 Hz, 1H), 2.23 (s, 2H), 1.71 (d,
J = 9.0 Hz, 3H), 1.56 (s, 3H); 13C NMR (75 MHz, CD3OD)
δC 159.8, 142.0, 137.0, 135.0, 130.5, 125.2, 124.1, 115.1, 112.4,
55.5, 49.4, 35.4, 34.2, 22.7, 12.5; (+)-HRMS (ESI) m/z calcd
for C15H20N3O [M + H]
+, 258.1601 ; found 258.1603.
Formation of Compound 9 by Copper-Catalyzed
Heteroarene Hydroxylation of 2-Iodohuperzine A (3). 2-
Iodohuperzine A (3, 0.14 mmol, 50 mg), copper(I) iodide (1
mg, 4 mol %), and K2CO3 (0.41 mmol, 56 mg) were charged
in a 15 mL sealed screw-capped tube under air, and 5.0 mL of
deionized water was added via a syringe. The sealed tube was
closed tightly after purging with argon gas flow. The reaction
mixture was heated at 140 °C and stirred for 72 h. After
cooling to room temperature, the reaction mixture was
quenched with H2O (10 mL) and extracted three times with
CH2Cl2 (10 mL). The combined organic layers were washed
with sat. NaCl (10 mL), then dried over anhydrous Na2SO4,
and concentrated under reduced pressure. The crude product
was purified by flash column chromatography (7−15% v/v




one (9). Yellowish solid; m.p. 83−85 °C; [α]D26 −151.2° (c 2.5,
CH3OH); Rf = 0.14 (10% v/v MeOH in CH2Cl2); IR (neat) ν
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3356, 2923, 1648, 1615, 1580, 1439 cm−1; 1H NMR (300
MHz, (CD3)2SO) δH 7.10 (s, 1H), 5.45 (q, J = 6.0 Hz, 1H),
5.38 (d, J = 4.5 Hz, 1H), 3.40−3.55 (m, 1H), 2.57 (dd, J =
18.0, 6.0 Hz, 1H), 2.40 (d, J = 18.0 Hz, 1H), 1.90−2.10 (m,
2H), 1.62 (d, J = 6.0 Hz, 3H), 1.49 (s, 3H); 13C NMR (75
MHz, (CD3)2SO) δC 158.3, 144.7, 142.1, 133.5, 130.2, 124.4,
121.2, 114.7, 110.4, 53.9, 48.3, 34.1, 32.4, 22.4, 12.1;
(+)-HRMS (ESI) m/z calcd for C15H19N2O2 [M + H]
+,
259.1447; found 259.1441.
Formation of Compound 10 by Copper-Catalyzed
Heteroarene Methoxylation of 2-Iodohuperzine A (3). 2-
Iodohuperzine A (3, 0.27 mmol, 100 mg), copper(I) iodide (2
mg, 4 mol %), and K2CO3 (0.81 mmol, 112 mg) were charged
in a 15 mL sealed screw-capped tube under air, and 5.0 mL of
methanol was added via a syringe. The sealed tube was closed
tightly after purging with argon gas flow. The reaction mixture
was heated at 140 °C and stirred for 120 h. The crude mixture
was filtered through a patch of silica gel and washed with
MeOH. The crude product was purified by flash column
chromatography (7% v/v MeOH in ethyl acetate) to afford 2-
methoxyhuperzine A (10, 49 mg, 66%).
(5R,9R,E)-5-Amino-11-ethylidene-3-methoxy-7-methyl-
5,6,9,10-tetrahydro-5,9-methanocycloocta[b]pyridin-2(1H)-
one (10). Brownish solid; m.p. 90−91 °C; [α]D26 −89.0° (c 2.0,
CH3OH); Rf = 0.18 (7% v/v MeOH in CH2Cl2); IR (neat) ν
2910, 1647, 1620, 1571, 1462, 1247 cm−1; 1H NMR (300
MHz, (CD3)2SO) δH 7.22 (s, 1H), 5.48 (q, J = 6.0 Hz, 1H),
5.37 (d, J = 3.0 Hz, 1H), 3.83 (s, 3H), 3.47−3.53 (m, 1H),
2.55 (dd, J = 18.0, 6.0 Hz, 1H), 2.53 (d, J = 18.0 Hz, 1H), 2.05
(s, 2H), 1.61 (d, J = 6.0 Hz, 3H), 1.49 (s, 3H); 13C NMR (75
MHz, (CD3)2SO) δC 157.0, 147.3, 142.1, 133.5, 131.7, 124.4,
120.1, 113.6, 110.4, 55.3, 54.0, 48.2, 34.0, 32.3, 22.4, 12.1;
(+)-HRMS (ESI) m/z calcd for C16H21N2O2 [M + H]
+,
273.1598; found 273.1597.
Formation of Compound 11 by Copper-Catalyzed
Heteroarene Ethoxylation of 2-Iodohuperzine A (3). 2-
Iodohuperzine A (3, 0.14 mmol, 50 mg), copper(I) iodide (1
mg, 4 mol %), and K2CO3 (0.41 mmol, 56 mg) were charged
in a 15 mL sealed screw-capped tube under air, and 5.0 mL of
ethanol was added via a syringe. The sealed tube was closed
tightly after purging with argon gas flow. The reaction mixture
was heated at 140 °C and stirred for 72 h. The crude mixture
was filtered through a patch of silica gel and washed with
ethanol. The crude product was purified by flash column
chromatography (7−15% v/v MeOH in CH2Cl2) to afford 2-
ethoxyhuperzine A (11, 11 mg, 29%).
(5R,9R,E)-5-Amino-3-ethoxy-11-ethylidene-7-methyl-
5,6,9,10-tetrahydro-5,9-methanocycloocta[b]pyridin-2(1H)-
one (11). Yellowish solid; m.p. 104 °C; [α]D
26 −61.3° (c 1.5,
CH3OH); Rf = 0.09 (10% v/v MeOH in CH2Cl2); IR (neat) ν
2926, 1647, 1618, 1569, 1455, 1246 cm−1; 1H NMR (300
MHz, CD3OD) δH 7.33 (s, 1H), 5.53 (q, J = 6.0 Hz, 1H), 5.45
(d, J = 6.0 Hz, 1H), 4.04 (q, J = 6.0 Hz, 2H), 3.60−3.70 (m,
1H), 2.76 (dd, J = 18.0, 6.0 Hz, 1H), 2.55 (dd, J = 18.0, 3.0
Hz, 1H), 2.27 (s, 2H), 1.72 (d, J = 6.0 Hz, 3H), 1.57 (s, 3H),
1.41 (t, J = 6.0 Hz, 3H); 13C NMR (75 MHz, CD3OD) δC
160.3, 148.3, 140.9, 134.8, 133.9, 125.2, 122.1, 115.7, 112.9,
65.5, 56.0, 48.8, 35.3, 34.0, 22.7, 14.8, 12.5; (+)-HRMS (ESI)
m/z calcd for C17H23N2O2 [M + H]
+, 287.1754; found
287.1751.
Formation of Compound 12 by Copper-Catalyzed
Heteroarene Alkoxylation of 2-Iodohuperzine A (3). 2-
Iodohuperzine A (3, 0.54 mmol, 200 mg), copper(I) iodide
(4 mg, 4 mol %), and K2CO3 (1.63 mmol, 225 mg) were
charged in a 15 mL sealed screw-capped tube under air, and
5.0 mL of n-propanol was added via a syringe. The sealed tube
was closed tightly after purging with argon gas flow. The
reaction mixture was heated at 140 °C and stirred for 72 h.
The crude mixture was filtered through a patch of silica gel and
washed with n-propanol. The crude product was purified by
flash column chromatography (7−15% v/v MeOH in CH2Cl2)
to afford 2-propoxyhuperzine A (12, 107 mg, 66%).
(5R,9R,E)-5-Amino-11-ethylidene-7-methyl-3-propoxy-
5,6,9,10-tetrahydro-5,9-methanocycloocta[b]pyridin-2(1H)-
one (12). Yellowish solid; m.p. 109−111 °C; [α]D26 −67.5° (c
3.2, CH3OH); Rf = 0.26 (10% v/v MeOH in CH2Cl2); IR
(neat) ν 2922, 1650, 1613, 1572, 1455, 1263 cm−1; 1H NMR
(300 MHz, CD3OD) δH 7.32 (s, 1H), 5.53 (q, J = 6.5 Hz, 1H),
5.47 (d, J = 4.2 Hz, 1H), 3.94 (t, J = 6.6, 2H), 3.60−3.69 (m,
1H), 2.76 (dd, J = 16.5, 6.0 Hz, 1H), 2.53 (dd, J = 16.5, 3.0
Hz, 1H), 2.29 (s, 2H), 1.86 (sep, J = 6.0, 2H), 1.73 (d, J = 6.0
Hz, 3H), 1.58 (s, 3H), 1.06 (t, J = 6.0 Hz, 3H); 13C NMR (75
MHz, CD3OD) δC 160.3, 148.5, 140.6, 134.7, 133.9, 125.2,
121.8, 115.5, 113.1, 71.6, 56.2, 48.7, 35.3, 34.0, 23.3, 22.7, 12.5,
10.8; (+)-HRMS (ESI) m/z calcd for C18H25N2O2 [M + H]
+,
301.1911; found 301.1909.
Formation of Compound 13 by Copper-Catalyzed
Heteroarene Alkoxylation of 2-Iodohuperzine A (3). 2-
Iodohuperzine A (3, 0.54 mmol, 200 mg), copper(I) iodide
(4 mg, 4 mol %), and K2CO3 (1.63 mmol, 225 mg) were
charged in a 15 mL sealed screw-capped tube under air, and
5.0 mL of n-butanol was added via a syringe. The sealed tube
was closed tightly after purging with argon gas flow. The
reaction mixture was heated at 140 °C and stirred for 72 h.
The crude mixture was filtered through a patch of silica gel and
washed with n-butanol. The crude product was purified by
flash column chromatography (7−15% v/v MeOH in CH2Cl2)
to afford 2-butoxyhuperzine A (13, 109 mg, 64%).
(5R,9R,E)-5-Amino-3-butoxy-11-ethylidene-7-methyl-
5,6,9,10-tetrahydro-5,9-methanocycloocta[b]pyridin-2(1H)-
one (13). Brownish solid; m.p. 110−111 °C; [α]D26 −127.3° (c
1.1, CH3OH); Rf = 0.57 (10% v/v MeOH in CH2Cl2); IR
(neat) ν 2925, 1648, 1619, 1571, 1464, 1246 cm−1; 1H NMR
(300 MHz, CD3OD) δH 7.34 (s, 1H), 5.55 (q, J = 6.0 Hz, 1H),
5.43 (d, J = 3.0 Hz, 1H), 3.97 (t, J = 6.0, 2H), 3.60−3.70 (m,
1H), 2.74 (dd, J = 18.0, 6.0 Hz, 1H), 2.51 (d, J = 18.0 Hz, 1H),
2.22 (s, 1H), 2.21 (s, 1H), 1.75−1.85 (m, 2H), 1.71 (d, J = 6.0
Hz, 3H), 1.57 (s, 3H), 1.42−1.60 (m, 2H), 0.99 (t, J = 6.0 Hz,
3H); 13C NMR (75 MHz, CD3OD) δC 160.3, 148.4, 141.9,
135.1, 133.7, 125.2, 123.1, 116.1, 112.6, 69.7, 55.6, 49.3, 35.4,
34.1, 32.1, 22.7, 20.3, 14.2, 12.5; (+)-HRMS (ESI) m/z calcd
for C19H27N2O2 [M + H]
+, 315.2067; found 315.2067.
Formation of Compound 14 by O-Methylation of
Huperzine A (1). The mixture of HupA (1, 0.12 mmol, 30
mg) and Ag2CO3 (0.62 mmol, 171 mg) in CH2Cl2 (2.0 mL)
was treated with iodomethane (7.43 mmol, 0.5 mL) slowly at
room temperature for 45 h. The crude mixture was filtered
through celite and washed with CH2Cl2 (10 mL). The
combined organic layers were washed with sat. NaCl (5 mL),
then dried over anhydrous Na2SO4, and concentrated under
reduced pressure. The crude product was purified by flash
column chromatography (2−4% v/v MeOH in CH2Cl2) to
afford O-methylhuperzine A (14, 15 mg, 46%).
(5R,9R,E)-11-ethylidene-2-methoxy-7-methyl-9,10-dihy-
dro-5,9-methanocycloocta[b]pyridin-5(6H)-amine (14).
Clear viscous liquid; [α]D
26 −92.0° (c 1.0, CH3OH); Rf =
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0.40 (7% v/v MeOH in CH2Cl2); IR (neat) ν 2924, 1594,
1576, 1473, 1321, 1256 cm−1; 1H NMR (300 MHz, CDCl3)
δH 7.95 (d, J = 9.0 Hz, 1H), 6.57 (d, J = 9.0 Hz, 1H), 5.49 (q, J
= 6.0 Hz, 1H), 5.44 (d, J = 3.0 Hz, 1H), 3.87 (s, 3H), 3.60−
3.70 (m, 1H), 2.99 (dd, J = 18.0, 6.0 Hz, 1H), 2.85 (dd, J =
18.0, 3.0 Hz, 1H), 2.18 (s, 2H), 1.72 (d, J = 6.0 Hz, 3H), 1.51
(s, 3H); 13C NMR (75 MHz, CDCl3) δC 162.7, 153.6, 143.7,
136.7, 133.5, 133.0, 125.1, 110.7, 108.2, 55.4, 53.5, 50.7, 40.5,
34.0, 22.8, 12.6; (+)-HRMS (ESI) m/z calcd for C16H21N2O
[M + H]+, 257.1648; found 257.1649.
Formation of Compounds 15−17 by N-Methylation of
Huperzine A (1). The mixture of HupA (1, 1.03 mmol, 250
mg) and Ag2CO3 (5.16 mmol, 1.42 g) in CH2Cl2 (5.0 mL) was
treated with iodomethane (61.90 mmol, 3.9 mL) slowly at
room temperature for 72 h. The crude mixture was filtered
through celite and washed with CH2Cl2 (10 mL). The
combined organic layers were washed with sat. NaCl (5 mL),
then dried over anhydrous Na2SO4, and concentrated under
reduced pressure. The crude product was purified by flash
column chromatography (2−4% v/v MeOH in CH2Cl2) to
afford N,N,O-trimethylhuperzine A (15, 56 mg, 19%), N,N,N′-
trimethylhuperzine A (16, 76 mg, 26%), and N,N-dimethylhu-
perzine A (17, 28 mg, 10%).
(5R,9R,E)-11-Ethylidene-2-methoxy-N,N,7-trimethyl-9,10-
dihydro-5,9-methanocycloocta[b]pyridin-5(6H)-amine (15).
Clear viscous liquid; [α]D
26 −15.0° (c 2.0, CH3OH); Rf = 0.80
(7% v/v MeOH in CH2Cl2); IR (neat) ν 2924, 1592, 1575,
1473, 1359, 1254 cm−1; 1H NMR (300 MHz, CDCl3) δH 7.63
(d, J = 6.0 Hz, 1H), 6.51 (d, J = 6.0 Hz, 1H), 5.48 (q, J = 6.0
Hz, 1H), 5.35 (d, J = 3.0 Hz, 1H), 3.87 (s, 3H), 3.54−3.64 (m,
1H), 2.94 (dd, J = 18.0, 6.0 Hz, 1H), 2.87 (s, 3H), 2.74 (dd, J
= 18.0, 3.0 Hz, 1H), 2.64 (s, 1H), 2.12 (s, 3H), 2.10 (s, 1H),
1.69 (d, J = 6.0 Hz, 3H), 1.50 (s, 3H); 13C NMR (75 MHz,
CDCl3) δC 162.2, 154.2, 138.5, 137.5, 133.9, 132.5, 124.9,
113.3, 107.8, 63.3, 53.3, 47.9, 40.6, 39.9, 39.4, 34.5, 23.2, 12.5;





one (16). Clear viscous liquid; [α]D
26 −11.0° (c 2.5, CH3OH);
Rf = 0.57 (7% v/v MeOH in CH2Cl2); IR (neat) ν 1649, 1577,
1538, 1416 cm−1; 1H NMR (300 MHz, CDCl3) δH 7.45 (d, J =
9.0 Hz, 1H), 6.42 (d, J = 12.0 Hz, 1H), 5.42 (q, J = 6.0 Hz,
1H), 5.28 (d, J = 3.0 Hz, 1H), 3.50−3.60 (m, 1H), 3.41 (s,
3H), 2.80 (s, 3H), 2.71 (dd, J = 15.0, 6.0 Hz, 1H), 2.64 (dd, J
= 15.0, 3.0 Hz, 2H), 2.13 (s, 3H), 2.03 (d, J = 15.0 Hz, 1H),
1.63 (d, J = 9.0 Hz, 3H), 1.53 (s, 3H); 13C NMR (75 MHz,
CDCl3) δC 163.4, 144.0, 138.5, 136.4, 135.3, 124.0, 123.1,
117.3, 113.9, 62.6, 46.1, 40.0, 39.2, 35.6, 33.6, 31.0, 23.0, 12.5;





one (17). Clear viscous liquid; [α]D
26 −51.4° (c 1.4, CH3OH);
Rf = 0.02 (7% v/v MeOH in CH2Cl2); IR (neat) ν 2923, 1654,
1614, 1459, 1260 cm−1; 1H NMR (300 MHz, CDCl3) δH 7.57
(d, J = 9.0 Hz, 1H), 6.39 (d, J = 9.0 Hz, 1H), 5.45 (q, J = 6.0
Hz, 1H), 5.35 (s, 1H), 3.50−3.56 (m, 1H), 2.84 (s, 3H), 2.62
(d, J = 15.0 Hz, 2H), 2.20 (s, 3H), 2.02 (d, J = 18.0 Hz, 2H),
1.65 (d, J = 6.0 Hz, 1H), 1.56 (s, 3H); 13C NMR (75 MHz,
CDCl3) δC 165.1, 143.6, 141.4, 137.1, 134.8, 124.2, 122.8,
117.0, 114.2, 62.4, 46.3, 40.3, 39.2, 34.9, 33.5, 23.2, 12.5;
(+)-HRMS (ESI) m/z calcd for C17H23N2O [M + H]
+,
271.1805; found 271.1805.
Formation of Compound 18 by Acetylation of Huperzine
A (1). Hup A 1 (0.33 mmol, 80 mg) was reacted with acetic
anhydride (5.67 mmol, 532 μL) in CH2Cl2 (2.0 mL) at room
temperature for 2 h. The reaction mixture was quenched with
H2O (10 mL) and extracted three times with CH2Cl2 (10 mL).
The combined organic layers were washed with sat. NaCl (10
mL), then dried over anhydrous Na2SO4, and concentrated
under reduced pressure. The crude product was purified by
flash column chromatography (5% v/v MeOH in CH2Cl2) to
afford N-acetylhuperzine A (18, 60 mg, 64%).
N-((5R,9R,E)-11-Ethylidene-7-methyl-2-oxo-2,6,9,10-tetra-
hydro-5,9-methanocycloocta[b]pyridin-5(1H)-yl)acetamide
(18). White solid; m.p. 180 °C (decomposed); [α]D
26 +15.0° (c
1.0, CH3OH); Rf = 0.20 (5% v/v MeOH in CH2Cl2); IR
(neat) ν 3271, 2932, 1656, 1614, 1555, 1453, 1555, 1453,
1374, 1298, 835 cm−1; 1H NMR (400 MHz, CDCl3) δH 7.44
(d, J = 9.5 Hz, 1H), 6.40 (d, J = 9.5 Hz, 1H), 5.43 (br s, 1H),
5.30 (q, J = 7.0 Hz, 1H), 3.60 (br s, 1H), 2.96 (dd, J = 15.0, 4.8
Hz, 1H), 2.72 (d, J = 15.0 Hz, 1H), 2.27 (d, J = 6.0 Hz, 1H),
2.23 (d, J = 6.0 Hz, 1H), 2.08 (s, 3H), 1.67 (d, J = 7.0 Hz,
3H), 1.55 (s, 3H); 13C NMR (100 MHz, CDCl3) δC 175.2,
165.1, 142.5, 139.0, 134.7, 124.8, 120.1, 118.5, 114.5, 112.8,
58.4, 49.4, 34.5, 32.6, 34.3, 22.5, 12.5; HRMS (ESI-TOF) m/z
calcd for C17H20N2O2 [M + H]
+, 285.1525; found 285.1573.
Formation of Compound 20 by Amine Protection of
Huperzine A (1). To an oven-dried sealed tube were added
huperzine A (1) (0.5 mmol, 121 mg), CH2Cl2 (1.1 mL), and
Et3N (1.0 mmol, 0.14 mL). The reaction mixture was stirred
for 5 min and cooled to 0 °C. Trifluoroacetic anhydride (1.5
equiv, 0.1 mL) was added dropwise over 5 min. The resulting
mixture was allowed to warm to room temperature and stirred
for 20 h. The reaction mixture was washed with sat.
NaHCO3(aq) (10 mL). The aqueous layer was extracted
with EtOAc (10 mL). The combined organic layer was washed
with brine (10 mL), dried over Na2SO4, and concentrated in
vacuo to provide the crude product. The crude mixture was
filtered through a patch of silica gel and washed with 10%




5,9-methanocycloocta[b]pyridine (20). White solid; m.p.
192−195 °C; [α]D26 −9.6° (c 2.3, CH3OH); Rf = 0.30 ( 10%
v/v MeOH in CH2Cl2); IR(neat) ν 3217, 3026, 2908, 1728,
1651, 1612, 1550, 1453, 1186, 1151, 834, 727 cm−1; 1H NMR
(400 MHz, CDCl3) δH 7.35 (d, J = 9.5 Hz, 1H), 6.43 (d, J =
9.5, 1H), 6.31 (s, 1H), 5.45 (br s, 1H), 5.24 (q, J = 8.0 Hz,
1H), 3.64 (br. s, 1H), 2.97 (dd, J = 17.0, 5.0 Hz, 1H), 2.71 (d,
J = 16.0, 1H), 2.40 (d, J = 16.0 Hz, 2H), 1.69 (d, J = 8.0 Hz,
3H), 1.58 (s, 3H); 13C NMR (75 MHz, CDCl3) δC 165.0,
155.8 (q, 144.4), 143.2, 138.2, 133.3, 132.4, 124.6, 118.2,
115.7 (q, 62.4), 113.3, 59.4, 46.9, 34.4, 32.6, 22.5, 12.5; HRMS
(ESI-TOF) m/z calcd for C17H18F3N2O2[M + H]
+, 339.1315;
found 339.1312.
Formation of Compound 21 by Amine Protection of
Huperzine A (1). Huperzine A (1) (0.21 mmol, 50 mg) was
reacted with Boc2O (1.03 mmol, 225 mg), DMAP (0.08 mmol,
10 mg), and Et3N (0.62 mmol, 86 μL) in CH2Cl2 (1.0 mL) at
room temperature for 1.5 h. H2O (10 mL) was added, and the
mixture was extracted three times with CH2Cl2 (10 mL). The
combined organic layers were washed with sat. NaCl (10 mL),
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then dried over anhydrous Na2SO4, and evaporated under
reduced pressure. The crude product was purified by flash
column chromatography (10% v/v MeOH in CH2Cl2) to
afford N-tert-butyloxycarbonylhuperzine A (21, 20 mg, 29%).
tert-Butyl-((5R,9R,E)-11-ethylidene-7-methyl-2-oxo-
2,6,9,10-tetrahydro-5,9-methanocycloocta[b]pyridin-5(1H)-
yl)carbamate (21). White solid; [α]D
26 −56.4° (c 1.1,
CH3OH); Rf = 0.20 (10% v/v MeOH in CH2Cl2); IR
(neat) ν 2927, 1758, 1584, 1229, 1143 cm−1; 1H NMR (300
MHz, CDCl3) δH 8.21 (d, J = 9.0 Hz, 1H), 6.95 (d, J = 9.0 Hz,
1H), 5.52 (q, J = 6.0 Hz, 1H), 5.44 (d, J = 6.0 Hz, 1H), 3.60−
3.69 (m, 1H), 3.05 (dd, J = 18.0, 6.0 Hz, 1H), 2.94 (dd, J =
18.0, 3.0 Hz, 1H), 2.22 (br s, 2H), 1.73 (d, J = 9.0 Hz, 3H),
1.54 (s, 9H), 1.51 (s, 3H); 13C NMR (75 MHz, CDCl3) δC
155.91, 155.57, 151.46, 142.69, 139.08, 137.66, 133.2, 125.0,
113.4, 111.5, 83.8, 55.6, 50.7, 40.1, 33.7, 27.7 (3C), 22.5, 12.5.
(+)-HRMS (ESI) m/z calcd for C20H27N2O3 [M + H]
+,
343.2016; found 343.2018.
Formation of Compound 22 by Bromination of N-
Acetylhuperzine A (18). N-Acetylhuperzine A (18) (0.07
mmol, 19 mg) was reacted with CuBr2 (0.08 mmol, 19 mg) in
acetonitrile (2.0 mL) under an Ar atmosphere at 50 °C for 17
days. The reaction mixture was quenched with H2O (10 mL)
and extracted three times with CH2Cl2 (10 mL). The
combined organic layers were washed with sat. NaCl (10
mL), then dried over anhydrous Na2SO4, and evaporated
under reduced pressure. The crude product was purified by
flash column chromatography (5% v/v MeOH in CH2Cl2) to
afford 2-bromo-N-acetylhuperzine A (22, 21 mg, 86%).
N-((5R,9R,E)-3-Bromo-11-ethylidene-7-methyl-2-oxo-
2,6,9,10-tetrahydro-5,9-methanocycloocta[b]pyridin-5(1H)-
yl)acetamide (22). Pale yellow solid; m.p. 180 °C (decom-
posed); [α]D
26 −29.0° (c 4.2, CH3OH); Rf = 0.70 (5% v/v
MeOH in CH2Cl2); IR (neat) ν 3282, 2929, 1646, 1616, 1548,
1450, 1377, 1294, 1258, 1024, 952, 789, 735 cm−1; 1H NMR
(400 MHz, CDCl3) δH 7.74 (s, 1H), 5.45 (d, J = 4.8 Hz, 1H),
5.29 (q, J = 6.8 Hz, 1H), 3.63 (br s, 1H), 2.93 (dd, J = 5.6, 4.4
Hz, 1H), 2.63 (d, J = 15.6 Hz, 1H), 2.21 (d, J = 12.0 Hz, 1H),
2.11 (s, 1H), 2.08 (s, 3H), 1.60 (d, J = 6.8 Hz, 3H), 1.56 (s,
3H); 13C NMR (100 MHz, CDCl3) δC 167.7, 159.7, 141.1,
139.7, 132.7, 131.4, 123.8, 119.9, 112.3, 57.0, 33.3, 31.5, 29.1,
23.2, 21.5, 21.4, 11.5; HRMS (ESI-TOF) m/z calcd for
C17H20
79BrN2O2 [M + H]
+, 363.0630; found 363.0703.
Formation of Compound 23 by Iodination of N-
Acetylhuperzine A (18). N-Acetylhuperzine A (18) (0.11
mmol, 28 mg) was reacted with NIS (0.17, 15 mg) in CH2Cl2
(1.0 mL) at room temperature for 5.5 h. The reaction mixture
was quenched with H2O (10 mL) and extracted three times
with CH2Cl2 (10 mL). The combined organic layers were
washed with sat. NaCl (10 mL), then dried over anhydrous
Na2SO4, and evaporated under reduced pressure. The crude
product was purified by flash column chromatography (7% v/v




yl)acetamide (23). Pale yellow solid; m.p. 200 °C (decom-
posed); [α]D
26 −97.5° (c 3.2, CH3OH); Rf = 0.40 (5% v/v
MeOH in CH2Cl2); IR (neat) ν 3277, 3049, 2926, 2858, 1636,
1612, 1542, 1423, 1264, 1182, 732,7014, cm−1; 1H NMR (400
MHz, CDCl3) δH 7.89 (s, 1H), 5.46 (d, J = 8.4 Hz, 1H), 5.22
(q, J = 8.8 Hz, 1H), 3.50 (t, J = 4.0 Hz, 1H), 2.85 (dd, J = 12.8,
4.4 Hz, 1H), 2.55 (d, J = 16.8 Hz, 1H), 2.19 (s, 1H), 2.08 (s,
3H), 1.60 (d, J = 6.8 Hz, 3H), 1.51 (s, 3H); 13C NMR (100
MHz, CDCl3) δC 169.0, 161.8, 147.5, 143.4, 134.0, 132.5,
124.8, 123.0, 113.3, 58.0, 47.8, 34.4, 32.5, 29.7, 24.3, 22.5,
12.5; HRMS (ESI-TOF) m/z calcd for C17H20
127IN2O2 [M +
H]+, 411.0564; found 411.0562.
Biological Studies. AChE and BChE Inhibition Assays.
The AChE inhibition activity of HupA derivatives were
measured using the spectrometric method of Ellman.48 Briefly,
20 μL of the tested compound solution (dissolved in methanol
with DMSO as a solubilizing agent), 100 μL of phosphate
buffer (pH 8.0), and 20 μL of 3.3 mM 5,5′-dithiobis-2-
nitrobenzoic acid (DTNB) aqueous solution were transferred
into a 96-well plate. A total of 40 μL of 0.25 U/mL electric eel
acetylcholinesterase (eeAChE, Sigma-Aldrich) solution was
added into the mixture and incubated at 37 °C for 20 min.
After incubation, 20 μL of 5 mM acetylthiocholine iodide
(ATCI) was added and shaken gently. The absorbance was
measured at 412 nm every 20 s for 3 min using a microplate
reader with a UV−visible spectrometer to obtain the enzymatic
reaction rate (maximal velocity, Vmax). Phosphate buffer (pH
8.0) instead of AChE was used as the blank to obtain the
enzymatic reaction rate of the blank (Vblank). Donepezil
hydrochloride monohydrate instead of the tested compound
was used as the positive control, and methanol was used as the
negative control (Vcontrol).
The percentage inhibition activity of AChE of all HupA
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where Vcontrol = enzymatic reaction rate of control, Vblank =
enzymatic reaction rate of blank, and Vi = enzymatic reaction
rate of tested compound.
The inhibition activities of AChE of all HupA analogs were
expressed as the half-maximal inhibitory concentration (IC50)
using 8−10 different concentrations of each HupA analog. The
compounds with IC50 concentration more than 1000 μM was
considered as inactive. All determinations were carried out in
triplicate and expressed as mean ± standard error of the mean
(S.E.M.). For the BChE inhibition assay, experimental
procedures and calculations of the BChE inhibition activity
of HupA analogs were conducted similar to the methods
described previously, but using butyrylthiocholine iodide
(BTCI) instead of ATCI and BChE from equine serum (eq-
BChE) instead of eeAChE.
Cell Culture. The normal human lung fibroblast cell line
(IMR90) was purchased from the American Type Culture
Collection (ATCC; Manassas, VA, USA). Cells were cultured
in DMEM (Dulbecco’s Modified Eagle’s Medium) supple-
mented with 10% fetal bovine serum, 100 U/mL penicillin, and
100 μg/mL streptomycin. Cells were maintained under 5%
CO2 at 37 °C in humidified air.
MTT Assay. IMR90 cells were plated into 96-well plates at a
density of 5 × 104 cells/well. After 18 h of incubation, the
tested samples at the indicated concentrations were added into
triplicate wells. Cells were then incubated for 24 h. The cell
viability was determined using the MTT (3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Briefly, the
supernatant was removed. A total of 100 μL of the MTT
solution (0.5 mg MTT in 1.0 mL complete medium) was
added to each well. The cells were incubated at 37 °C for 3 h.
The solution was then replaced with 100 μL of DMSO. The
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absorbance was measured at 570 nm using a microplate reader
(Modular multimode microplate reader, Thermo Scientific). %
Cytotoxicity was calculated by comparing the absorbance of
the treated wells to the untreated control according to the
following equation: %Cytotoxicity = [1 − [Abs (sample)/Abs
(untreated control)]] × 100. The experiment was done in
triplicate.
Data Analysis and Statistical Methods. The data from the
experiment was expressed as mean ± standard error of mean
(S.E.M). One-way ANOVA and post hoc least-significant
difference (LSD) were used to determine the statistical
significance of the difference between groups. The association
between the estimated Ki value according to the docking
program and calculated Ki according to in vitro results used
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